Eplerenone

Generic Name: Eplerenone

Brand Names: Inspra

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₃₀O_₆

CAS Number: 107724-20-9

Unique Ingredient Identifier: 6995V82D0B

Background: Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. Eplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and androgen receptors.

Indication: For improvement of survival of stable patients with left ventricular systolic dysfunction (ejection fraction <40%) and clinical evidence of congestive heart failure after an acute myocardial infarction.

Associated Conditions: Hypertension, LVEF <40% Congestive heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class II)

Associated Therapies: -

Clinical Trials

CLCNKA (Ka Renal Chloride Channel[ClC-Ka]) Polymorphism Effects on Hypertrophy Regression

Phase 4

Withdrawn

Conditions: Hypertension

Interventions: Drug: placebo
Drug: Eplerenone

First Posted Date: 2011-01-12

Last Posted Date: 2015-06-03

Lead Sponsor: Washington University School of Medicine

Registration Number: NCT01275352

Locations: 🇺🇸
Barnes Jewish Hospital, St. Louis, Missouri, United States
🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Effect on Renal Potassium Clearance

Phase 1

Completed

Conditions: Chronic Kidney Disease

Interventions: Drug: LY2623091
Drug: Placebo
Drug: Eplerenone

First Posted Date: 2010-11-10

Last Posted Date: 2019-06-03

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 32

Registration Number: NCT01237899

Locations: 🇳🇱
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zuidlaren, Netherlands

Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction

Phase 4

Completed

Conditions: Myocardial Infarction

Interventions: Drug: Eplerenone
Drug: Placebo

First Posted Date: 2010-08-06

Last Posted Date: 2020-12-22

Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Target Recruit Count: 1012

Registration Number: NCT01176968

Locations: 🇸🇰
Univerzitna nemocnica Martin, Martin, Slovakia
🇸🇰
Vseobecna nemocnica Rimavska Sobota, Rimavska Sobota, Slovakia
🇸🇰
Kardiocentrum Nitra, s.r.o., Nitra, Slovakia

and more 71 locations

Clinical Study Of Eplerenone In Japanese Patients With Chronic Heart Failure

Phase 3

Completed

Conditions: Heart Failure

Interventions: Drug: Placebo
Drug: Eplerenone

First Posted Date: 2010-05-04

Last Posted Date: 2020-12-22

Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Target Recruit Count: 221

Registration Number: NCT01115855

Locations: 🇯🇵
Hakodate City Hospital, Hakodate, Hokkaido, Japan
🇯🇵
Hokkaido University Hospital, Sapporo, Hokkaido, Japan
🇯🇵
Hyogo Brain and Heart Center, Himeji, Hyogo, Japan

and more 51 locations

Aldosterone Blockade in Chronic Kidney Disease: Influence on Arterial Stiffness and Kidney Function

Phase 3

Terminated

Conditions: Chronic Kidney Disease

Interventions: Drug: Eplerenone

First Posted Date: 2010-04-08

Last Posted Date: 2012-02-08

Lead Sponsor: Lene Boesby

Target Recruit Count: 54

Registration Number: NCT01100203

Locations: 🇩🇰
Dept. Nephrology, Herlev Hospital, Herlev, Denmark
🇩🇰
Herlev Hospital, Herlev, Denmark

Aldosterone Blockade to Prevent Myocardial Remodeling In Patients With Controlled Essential Hypertension

Not Applicable

Terminated

Conditions: Myocardial Remodeling

Interventions: Drug: Eplerenone
Drug: Lactose Tablet

First Posted Date: 2009-09-18

Last Posted Date: 2014-03-28

Lead Sponsor: Creighton University

Target Recruit Count: 20

Registration Number: NCT00980031

Locations: 🇺🇸
Creighton University Medical Center (including ambulatory centers), Omaha, Nebraska, United States

A Study of the Effects of Eplerenone and Amlodipine on Blood Pressure and Basal Metabolic Rate in Obese Hypertensives

Not Applicable

Terminated

Conditions: Obesity
Hypertension

Interventions: Drug: eplerenone, amlodipine
Drug: eplerenone
Drug: amlodipine

First Posted Date: 2009-01-19

Last Posted Date: 2018-05-29

Lead Sponsor: University of Mississippi Medical Center

Target Recruit Count: 10

Registration Number: NCT00825188

Locations: 🇺🇸
The University of Mississippi Clinical Research Program, Jackson, Mississippi, United States

A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension

Phase 2

Completed

Conditions: Hypertension

Interventions: Drug: LCI699
Drug: LCI699-matching Placebo
Drug: Eplerenone
Drug: Eplerenone-matching Placebo

First Posted Date: 2009-01-06

Last Posted Date: 2021-06-02

Lead Sponsor: Novartis

Target Recruit Count: 155

Registration Number: NCT00817635

Locations: 🇺🇸
Horizon Research Group, Inc, Mobile, Alabama, United States
🇺🇸
Northwest Clinical Trials, Boise, Idaho, United States
🇺🇸
KRK Medical Research, Dallas, Texas, United States

and more 32 locations